BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nooijen LE, Swijnenburg RJ, Klümpen HJ, Verheij J, Kazemier G, van Gulik TM, Erdmann JI. Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art. Visc Med 2021;37:18-25. [PMID: 33708815 DOI: 10.1159/000514032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Cho SM, Esmail A, Raza A, Dacha S, Abdelrahim M. Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers (Basel) 2022;14:2641. [PMID: 35681621 DOI: 10.3390/cancers14112641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Simbolo M, Bersani S, Vicentini C, Taormina SV, Ciaparrone C, Bagante F, Rusev B, Centonze G, Montresor M, Brunelli M, Pedron S, Mafficini A, Paolino G, Mattiolo P, Conci S, Milione M, Guglielmi A, Ruzzenente A, Scarpa A, Luchini C. Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opin Ther Targets 2021;:1-11. [PMID: 34873971 DOI: 10.1080/14728222.2021.2013801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]